IRWD
IRONWOOD PHARMACEUTICALS INC
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$3.56
+1.71%Year over year
Reported trailing growth
- Revenue
- +26.2%
- EBITDA
- +148.7%
- EBIT
- +223.0%
- EPS
- +1946.9%
- Free cash flow
- +519.8%
- Operating cash flow
- +518.8%
Forward estimates
Based on analyst estimates
- Revenue
- +23.3%
- EBITDA
- +58.3%
- EPS
- +61.6%
Three-year CAGR
- Revenue
- -10.3%
- EBITDA
- -26.3%
- EBIT
- -22.0%
- Net income
- -48.4%
- EPS
- -49.0%
- Free cash flow
- -22.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026